EIK1004-001 (IMP1707-001) Clinical Trials

1 actively recruiting trial across 1 location

Filter by location:

Denver, Colorado1 trial

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Sarah Cannon Research Institute at HealthOne

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.